Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
NCT06145633
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) (mCRPC). Prostate cancer that has not spread to other parts of the body (localized) is typically treated through surgery or radiotherapy, which for many men is curable. Despite definitive local therapy, cancer that has come back after a period of improvement (recurrent) disease develops in 27-53% of men.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- Any age
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Fred Hutchinson Cancer Center
- Last updated on ClinicalTrials.gov
- August 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- Fred Hutch/University of Washington Cancer Consortium · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.